SS-31 side effects reported in trials include injection site reactions, headaches, and fatigue. Learn what the research shows and when to talk to a doctor.
SS-31 (elamipretide) has been described as generally well tolerated in the human trials completed to date. The most frequently reported ss 31 side effects are injection site reactions such as redness, tenderness, and swelling, followed by headache, nausea, and fatigue. No consistent organ toxicity signal has been identified, but SS-31 remains investigational, so its long-term safety profile is still unknown.
SS-31 is a synthetic tetrapeptide that binds to cardiolipin on the inner mitochondrial membrane. It is also studied under the names MTP-131, Bendavia, and Forzinity, and it has been tested in Barth syndrome, primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
SS-31 is not FDA-approved for any human indication as of this writing. Outside a clinical trial, products sold as SS-31 are unregulated, which means purity, sterility, and actual dose are not guaranteed.
Reported SS-31 Side Effects in Human Trials
Across completed early-phase studies, most adverse events were mild to moderate and resolved without treatment. The table below summarizes the effects reported most often.
| Side effect | How often it appeared | What researchers noted |
|---|---|---|
| Injection site reactions (redness, pain, swelling, itching) | Most common; reported by a notable share of participants | Usually mild and short-lived; rarely caused anyone to stop treatment |
| Headache | Common | Generally mild; resolved without intervention |
| Nausea | Occasional | More often linked to intravenous infusion than subcutaneous injection |
| Dizziness or lightheadedness | Occasional | Reported more often in older or frail participants |
| Fatigue | Occasional | Difficult to separate from the underlying disease |
| Serious adverse events | Similar rates in SS-31 and placebo groups in most trials | No consistent pattern tied to the drug |
These numbers come from small trials in rare diseases, so they should be read as signals rather than precise rates. Real-world risk can differ from what a short study of a few dozen participants shows.
Injection Site Reactions Are the Most Common Complaint
SS-31 is typically given as a subcutaneous injection, and most complaints start at the needle site. Common reactions include redness, tenderness, swelling, itching, and a small firm lump under the skin.
Clinicians running these trials have used a few standard strategies to reduce local irritation:
- Rotate injection sites and avoid reusing the same spot within a few days.
- Let the syringe sit at room temperature for a few minutes before injecting.
- Inject into clean, dry skin at a 45- to 90-degree angle.
- Avoid areas that are bruised, scarred, or inflamed.
Most injection site reactions fade within hours to a few days. A reaction that spreads, blisters, or comes with fever deserves prompt medical attention.
Side Effect Patterns Across Different Study Groups
The tolerability picture has been broadly similar across the conditions studied, even though the trial designs differ substantially.
| Study population | Typical regimen | Side effect signal |
|---|---|---|
| Barth syndrome | 40 mg subcutaneous daily | Mostly mild injection site reactions; serious events balanced across groups |
| Primary mitochondrial myopathy | 40 mg subcutaneous daily | Adverse event rates comparable to placebo |
| Heart failure and STEMI | Intravenous infusion | Infusion-related nausea and dizziness reported; no clear cardiac toxicity signal |
| Dry age-related macular degeneration | Subcutaneous or intravitreal, depending on the trial | Local and systemic events generally mild |
One recurring problem is attribution. Fatigue, muscle weakness, and exercise intolerance are core symptoms of the diseases being studied, so participants may report them whether or not the peptide caused them.
What Is Not Known About Long-Term SS-31 Use
No study has followed healthy adults taking SS-31 for years, so questions about cumulative effects, immune response, and drug interactions remain open. The same data gap appears with other research peptides; discussions of cjc 1295 long-term side effects run into the identical limit of missing human data.
Stacking compounds adds another layer of uncertainty. Conversations about aod 9604 and tirzepatide together side effects show how difficult it is to attribute a symptom to one product when several are used at once.
How SS-31 Compares With Other Injectable Products
People researching peptide safety often compare products that have little in common. What is reported about lipo c injection side effects, for example, reflects a vitamin and amino acid blend rather than a mitochondria-targeted peptide. Even familiar supplements have their own profiles, and l-carnitine side effects — usually gastrointestinal — say nothing about SS-31.
What these products do share is a regulatory gap. Compounded and gray-market injectables are not held to the same manufacturing standards as approved drugs, and contamination or dosing errors can cause reactions that have nothing to do with the active ingredient.
Safety Guidance and Red Flags
Anyone considering SS-31 should speak with a licensed healthcare professional first, particularly people who are pregnant or breastfeeding, take blood thinners, or have kidney or liver disease.
Seek medical care promptly if you notice any of the following:
- A severe, spreading, or blistering reaction at the injection site
- Fever, chills, or pus at the injection site
- Hives, facial swelling, or trouble breathing
- A persistent or worsening headache
- Unusual bruising, bleeding, or a rapid heartbeat
Suspected reactions to any injectable product can be reported to the FDA through the MedWatch program.
The Bottom Line
Available human data suggest SS-31 is reasonably well tolerated at the doses studied, with injection site reactions leading the list of complaints. That is not the same as proven long-term safety.
- Injection site reactions are the most commonly reported side effect of SS-31 in human trials.
- SS-31 is not FDA-approved for human use as of this writing.
- Long-term safety data for SS-31 in healthy adults do not exist.
- Anyone considering SS-31 should consult a licensed healthcare professional before use.
Frequently Asked Questions
What are the most common SS-31 side effects?
The most common side effects reported in human trials are injection site reactions such as redness, pain, swelling, and itching. Headache, nausea, dizziness, and fatigue also appear in trial data, usually at mild to moderate severity. Serious adverse events have generally occurred at rates similar to placebo.
Is SS-31 FDA-approved?
No. SS-31 (elamipretide) is not FDA-approved for any human indication as of this writing and remains an investigational drug. Access is limited to clinical trials or unregulated compounded and gray-market sources. Products from those sources are not guaranteed to be pure, sterile, or accurately dosed.
How long do SS-31 side effects last?
Most reported reactions are short-lived. Injection site reactions typically fade within hours to a few days, and headaches or nausea usually resolve without treatment. Any reaction that spreads, blisters, or comes with fever should be evaluated by a healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.